Sakar Healthcare Limited

NSEI:SAKAR Stock Report

Market Cap: ₹6.7b

Sakar Healthcare Past Earnings Performance

Past criteria checks 2/6

Sakar Healthcare has been growing earnings at an average annual rate of 12.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 15.8% per year. Sakar Healthcare's return on equity is 5.3%, and it has net margins of 8.2%.

Key information

12.5%

Earnings growth rate

5.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate15.8%
Return on equity5.3%
Net Margin8.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Dec 28
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Aug 05
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Mar 29
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Jan 31
Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Dec 01
Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Jul 13
Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Mar 26
Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Jul 01
With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23
Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02
Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08
Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14
Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22
Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Revenue & Expenses Breakdown
Beta

How Sakar Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:SAKAR Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,5181252010
30 Sep 231,4801442030
30 Jun 231,4381271890
31 Mar 231,3421281690
31 Dec 221,3021781690
30 Sep 221,2651391550
30 Jun 221,2651441520
31 Mar 221,2911521540
31 Dec 211,139801310
30 Sep 211,109971330
30 Jun 211,0541181340
31 Mar 219531071330
31 Dec 209131181370
30 Sep 208701221320
30 Jun 208841061300
31 Mar 20839961230
31 Dec 19851881140
30 Sep 19844861120
30 Jun 1974478980
31 Mar 1968867910
31 Mar 1853438690
31 Mar 1744734600
31 Mar 1641422500
31 Dec 1538624490
31 Mar 1535018400
31 Mar 1429718330

Quality Earnings: SAKAR has high quality earnings.

Growing Profit Margin: SAKAR's current net profit margins (8.2%) are lower than last year (13.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SAKAR's earnings have grown by 12.5% per year over the past 5 years.

Accelerating Growth: SAKAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SAKAR had negative earnings growth (-29.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).


Return on Equity

High ROE: SAKAR's Return on Equity (5.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.